{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:16:01Z","timestamp":1768400161080,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["98-2314-B-182A-082-MY3"],"award-info":[{"award-number":["98-2314-B-182A-082-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01HL105198"],"award-info":[{"award-number":["U01HL105198"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI15C1537"],"award-info":[{"award-number":["HI15C1537"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["HL065962"],"award-info":[{"award-number":["HL065962"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R24GM61374"],"award-info":[{"award-number":["R24GM61374"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["NHRI-EX100-9925SC"],"award-info":[{"award-number":["NHRI-EX100-9925SC"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004866","name":"National Research Program for Biopharmaceuticals","doi-asserted-by":"publisher","award":["101TM1033"],"award-info":[{"award-number":["101TM1033"]}],"id":[{"id":"10.13039\/501100004866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004866","name":"National Research Program for Biopharmaceuticals","doi-asserted-by":"publisher","award":["CMRPG3A1071"],"award-info":[{"award-number":["CMRPG3A1071"]}],"id":[{"id":"10.13039\/501100004866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG391861"],"award-info":[{"award-number":["CMRPG391861"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ahj.2017.12.010","type":"journal-article","created":{"date-parts":[[2017,12,17]],"date-time":"2017-12-17T10:04:12Z","timestamp":1513505052000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points\u2014Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)"],"prefix":"10.1016","volume":"198","author":[{"given":"Thomas O.","family":"Bergmeijer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Reny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth E.","family":"Pakyz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua P.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Aradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Fernandez-Cadenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Horenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Ta Michael","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M.","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Franco","family":"Gensini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Cleator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyuk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Holmvang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willibald","family":"Hochholzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russ B.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"D\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinrad","family":"Gawaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Schaeffeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia P.","family":"Dridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Shien","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tabassome","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betti","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Sebastien","family":"Hulot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Braxton D.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylyn DeRiggi","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teri E.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Shuldiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ahj.2017.12.010_bb0005","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.4244\/EIJY14M09_01","article-title":"2014 ESC\/EACTS guidelines on myocardial revascularization","volume":"10","author":"Windecker","year":"2015","journal-title":"EuroIntervention"},{"issue":"23","key":"10.1016\/j.ahj.2017.12.010_bb0010","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: A report of the American College of cardiology Foundation\/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2017.12.010_bb0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ahj.2016.02.018","article-title":"Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb\/IIIa inhibitor treatment: a nationwide Swedish registry report","volume":"176","author":"Grimfjard","year":"2016","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.ahj.2017.12.010_bb0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.010_bb0025","first-page":"1","article-title":"Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"issue":"9038","key":"10.1016\/j.ahj.2017.12.010_bb0030","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ahj.2017.12.010_bb0035","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.ahj.2017.12.010_bb0040","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"10.1016\/j.ahj.2017.12.010_bb0045","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.ahj.2017.12.010_bb0050","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.010_bb0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole CLopidogrel aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.010_bb0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jth.12445","article-title":"Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors","volume":"12","author":"Siller-Matula","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.010_bb0065","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ahj.2011.06.005","article-title":"Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy","volume":"162","author":"Hochholzer","year":"2011","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2017.12.010_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2013.03.037","article-title":"The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study","volume":"62","author":"Gurbel","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.010_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.010_bb0085","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","article-title":"The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects","volume":"6","author":"Umemura","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.ahj.2017.12.010_bb0090","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ahj.2017.12.010_bb0095","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.010_bb0100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2007.11.065","article-title":"Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome","volume":"101","author":"Frere","year":"2008","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.010_bb0105","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","article-title":"CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation","volume":"9","author":"Geisler","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.ahj.2017.12.010_bb0110","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients","volume":"17","author":"Giusti","year":"2007","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0115","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcin.2011.03.002","article-title":"High doses of clopidogrel to overcome genetic resistance: The randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)","volume":"4","author":"Collet","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"9660","key":"10.1016\/j.ahj.2017.12.010_bb0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ahj.2017.12.010_bb0125","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","article-title":"CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study","volume":"31","author":"Harmsze","year":"2010","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.ahj.2017.12.010_bb0130","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.010_bb0135","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/pgs.11.73","article-title":"Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention","volume":"12","author":"Rideg","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"20","key":"10.1016\/j.ahj.2017.12.010_bb0140","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2017.12.010_bb0150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Scott","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2017.12.010_bb0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","article-title":"Molecular basis of ethnic differences in drug disposition and response","volume":"41","author":"Xie","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.thromres.2011.07.022","article-title":"CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention","volume":"129","author":"Kassimis","year":"2012","journal-title":"Thromb Res"},{"issue":"15","key":"10.1016\/j.ahj.2017.12.010_bb0170","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/hrt.2010.220509","article-title":"Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting","volume":"97","author":"Bouman","year":"2011","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.ahj.2017.12.010_bb0175","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1538-7836.2012.04756.x","article-title":"PON1 Meta-Analysis Group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis","volume":"10","author":"Reny","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"9749","key":"10.1016\/j.ahj.2017.12.010_bb0180","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.010_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/FPC.0b013e32834ff6e3","article-title":"The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting","volume":"22","author":"Harmsze","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0190","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.010_bb0195","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jth.12342","article-title":"The CYP2C19*17 variant is not independently associated with clopidogrel response","volume":"11","author":"Lewis","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ahj.2017.12.010_bb0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cpt.401","article-title":"Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity","volume":"100","author":"Scott","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.010_bb0205","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2011.04409.x","article-title":"Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study","volume":"9","author":"Fontana","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"22","key":"10.1016\/j.ahj.2017.12.010_bb0210","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2017.12.010_bb0215","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2017.12.010_bb0220","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ahj.2017.12.010_bb0225","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.010_bb0230","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2017.12.010_bb0235","first-page":"1.19.1","article-title":"Quality control procedures for genome-wide association studies","volume":"68","author":"Turner","year":"2011","journal-title":"Curr Protoc Hum Genet"},{"key":"10.1016\/j.ahj.2017.12.010_bb0240","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fgene.2014.00370","article-title":"Imputation and quality control steps for combining multiple genome-wide datasets","volume":"5","author":"Verma","year":"2014","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.ahj.2017.12.010_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0102701","article-title":"Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention","volume":"9","author":"Siller-Matula","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0250","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.ijcard.2013.06.014","article-title":"Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial","volume":"168","author":"Xie","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2017.12.010_bb0255","first-page":"1","article-title":"Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome","author":"Paarup Dridi","year":"2014","journal-title":"Platelets"},{"issue":"11","key":"10.1016\/j.ahj.2017.12.010_bb0260","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ahj.2017.12.010_bb0265","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2017.12.010_bb0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.ahj.2017.12.010_bb0275","first-page":"844","article-title":"Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data","volume":"115","author":"Reny","year":"2016","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.ahj.2017.12.010_bb0280","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCRESAHA.115.307016","article-title":"Platelet-mediated thrombosis: from bench to bedside","volume":"118","author":"Gurbel","year":"2016","journal-title":"Circ Res"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:33Z","timestamp":1762077393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317303988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":56,"alternative-id":["S0002870317303988"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.12.010","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points\u2014Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}